FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.395,05 +759,52 (+1,23%)
Guerbet SA (0ELV.L)
| Chiusura precedente | 37,70 |
| Aperto | 38,05 |
| Denaro | 0,00 x N/D |
| Domanda | 0,00 x N/D |
| Min-Max giorno | 38,05 - 38,05 |
| Intervallo di 52 settimane | 15,70 - 38,05 |
| Volume | |
| Media Volume | 1.642 |
| Capitalizzazione | 474,913M |
| Beta (mensile su 5 anni) | 0,74 |
| Rapporto PE (ttm) | 0,15 |
| EPS (ttm) | 2,58 |
| Prossima data utili | 25 set 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGuerbet: CHMP positive opinion
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European Commission, Elucirem™ (Gadopiclenol) will mark a step forward in innovation in MRI contrast media, thus answering to the Health authorities recommendation and concerns of patients and radiologists in Europe. An MRI exam with Elucirem™ r
- GlobeNewswire
Guerbet: 2023 half-year results
Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first half-year: €45.9 million, compared to €50.5 million one year earlierThe restated EBITDA margin2 amounted to 12.7% of revenue 2023 objectives confirmed Revenue: expected growth of more than 5% on a like-for-like basis and at CERExpected restated EBITDA margin2 around 11%,
